TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25982590
Drug: Intravenous carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous carbamazepine (administered at 70% of the oral dosage, mean 675.1 mg) infused over 30 min
Study: 25982590
Drug: Intravenous carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous carbamazepine (administered at 70% of the oral dosage, mean 675.1 mg) infused over 15 min
Study: 25982590
Drug: Intravenous carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous carbamazepine (administered at 70% of the oral dosage, mean 675.1 mg) with rapid infusions (2-5 min)
Study: 25982590
Drug: Oral carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral carbamazepine (mean 962.5 mg)
Study: 15166555
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion of 25 ng.kg(‐1).min(‐1)
Study: 15166555
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion of 50 ng.kg(‐1).min(‐1)
Study: 15166555
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion of 100 ng.kg(‐1).min(‐1)
Study: 15166555
Drug: Propofol in
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol in combination with remifentanil
Study: 3277912
Drug: Triamterene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (50 mg)
Study: 3277912
Drug: Oxprenolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (160 mg)
Study: 3277912
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chlorthalidone and triamterene
Study: 27188814
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg DHA/day (3 capsules daily)
Study: 22409211
Drug: Ivabradine 7.5
Normalized name: ivabradine 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 7.5 mg twice daily for 5 days
Study: 15916852
Drug: Incorrect *G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorrect *G condition (e.g., He happened using it)
Study: 15916852
Drug: Incorrect *I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorrect *I condition (e.g., He postponed to use it)
Study: 15531473
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment at 1 or 2 mg GH/m² body surface.d (approximately 0.035 or 0.07 mg/kg.d)
Study: 3924084
Drug: High-dose alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alfentanil anaesthesia (150 micrograms kg‐1 initially, followed by continuous infusion at a rate of 3 micrograms kg‐1 min‐1)
Study: 3924084
Drug: Neurolept anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurolept anaesthesia (droperidol 0.25 mg kg‐1 plus fentanyl 5 micrograms kg‐1 initially, followed by intermittent incremental doses of fentanyl 50 micrograms)
Study: 3924084
Drug: High-dose alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alfentanil anaesthesia
Study: 2455132
Drug: verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (120 mg b.i.d.)
Study: 2455132
Drug: nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (20 mg b.i.d.)
Study: 31439812
Drug: Niraparib 100
Normalized name: niraparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 100 mg
Study: 31439812
Drug: Niraparib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (all doses)
Study: 21317163
Drug: Trial interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial interventions (subject involvement, weekly phone reminders, routine counselling)
Study: 16525107
Drug: Ethionamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethionamide (250 mg or 500 mg, six times a week)
Study: 16525107
Drug: Prothionamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothionamide (250 mg or 500 mg, six times a week)
Study: 16525107
Drug: Ethionamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethionamide (500 mg)
Study: 16525107
Drug: Prothionamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothionamide (500 mg)
Study: 16525107
Drug: Prothionamide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothionamide (both dose levels)
Study: 10217586
Drug: 23-valent PS
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent PS vaccine (control group)
Study: 370178
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic 1
Study: 370178
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic 2
Study: 370178
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic 3
Study: 26220149
Drug: Individualized dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dose of rapid‐acting insulin (2 ± 1 units, range 0‐4 units) administered immediately after resistance exercise
Study: 26220149
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin administered after resistance exercise
Study: 12680735
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg pergolide (D1/D2 receptor agonist)
Study: 12680735
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg bromocriptine (D2 receptor agonist)
Study: 7042030
Drug: Injection site
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site in the arm
Study: 7042030
Drug: Injection site
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site in the abdomen
Study: 30518425
Drug: Audencel (dendritic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audencel (dendritic cell-based immunotherapy)
Study: 24333009
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg orally every day for 5 years
Study: 20363596
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of 3.0 mmol of magnesium-chloride per kilogram of body weight in SES and SCS groups
Study: 20363596
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of 3.0 mmol of magnesium-chloride per kilogram of body weight in SES group
Study: 8775244
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mifepristone + 0.5 mg gemeprost
Study: 8775244
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone + 1.0 mg gemeprost
Study: 1615873
Drug: Flecainide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (300 mg) as a single oral loading dose
Study: 1615873
Drug: Amiodarone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (5 mg/kg as an intravenous bolus, followed by 1.8 g/day)
Study: 6528619
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of heparin
Study: 6528619
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of heparin
Study: 27359058
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (post-antiestrogen)
Study: 27359058
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (post-aromatase inhibitor)
Study: 16446681
Drug: Bolus treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus treatment (1,000 ml of water immediately before exercise)
Study: 16446681
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (250 ml of water immediately before exercise and 250 ml at minutes 15, 30, and 45)
Study: 11874392
Drug: Levormeloxifene 20-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levormeloxifene 20-160 mg
Study: 11874392
Drug: Levormeloxifene 2.5-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levormeloxifene 2.5-320 mg (single doses)
Study: 11874392
Drug: Levormeloxifene 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levormeloxifene 160 mg (multiple dosing)
Study: 8039625
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with 6 MU of interferon alfa-2a, three times weekly for 9 months (group 1)
Study: 8039625
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy with 6 MU of interferon alfa-2a for two 3-month cycles separated by a 6-month pause (group 2)
Study: 8039625
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (group 1)
Study: 8039625
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy (group 2)
Study: 31899948
Drug: Water containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water containing 1.8375 × 10^10 cfu/l of probiotics for 8 weeks
Study: 25535142
Drug: Intracoronary tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary tirofiban administration
Study: 22339984
Drug: Self-help manual
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help manual with standard care and treatment
Study: 12074792
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthesia injection for repeat biopsy
Study: 26954319
Drug: DFD‐01 (0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFD‐01 (0.05% betamethasone dipropionate in emollient spray)
Study: 25136645
Drug: Standard advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard advice on medical nutrition therapy (Control)
Study: 20608142
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml 2% lidocaine
Study: 20608142
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml 2% mepivacaine
Study: 15482535
Drug: lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine 100 mg/day for up to 5 years
Study: 9661540
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg during sternotomy and 30 mg/kg during initiation of cardiopulmonary bypass)
Study: 18363032
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg daily)
Study: 2123367
Drug: Moclobemide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (100 mg, 6 weeks)
Study: 2123367
Drug: Imipramine (33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (33 mg, 6 weeks)
Study: 26267747
Drug: Liposomal prostaglandin
Normalized name: Liposomal prostaglandin E1
DrugBank: Liposomal prostaglandin E1 (DB05391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal prostaglandin E1 (lipo‐PGE1) 20 μg/day diluted in 10 ml of normal saline, administered intravenously over 5 min starting 3 days before PCI and continuing for 4 days after PCI
Study: 26267747
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal saline 10 ml administered intravenously)
Study: 25055027
Drug: NAP SACC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAP SACC program (treatment group)
Study: 21777507
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP): 50 mg eq. on days 1 and 8, flexible dosing 25-100 mg eq. once-monthly
Study: 21777507
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting injectable (RIS-LAI): bi-weekly injections of 25 mg on days 8 and 22, flexible dosing (25-50 mg) starting from day 36
Study: 21777507
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PP and RIS-LAI)
Study: 19476477
Drug: Inhaled TI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled TI (25 U)
Study: 19476477
Drug: Inhaled TI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled TI (50 U)
Study: 19476477
Drug: Inhaled TI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled TI (100 U)
Study: 19476477
Drug: Subcutaneous RHI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous RHI (10 IU)
Study: 15051600
Drug: High-oleate meal
Normalized name: oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-oleate meal (50 g fat)
Study: 15051600
Drug: High-palmitate meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-palmitate meal (50 g fat)
Study: 15051600
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (15 g fat)
Study: 12113542
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (chewed three times a day from the first postoperative AM until oral intake)
Study: 9728846
Drug: Acetated Ringer's
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer's solution during isoflurane anesthesia
Study: 2491990
Drug: Short-term administration
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term administration of Buserelin (day 1)
Study: 1120556
Drug: Perexiline maleate
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perexiline maleate at 400 mg/die
Study: 1120556
Drug: Prenilamine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenilamine at 120 mg/die
Study: 30102427
Drug: BUP/SAM 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP/SAM 2 mg/2 mg
Study: 30102427
Drug: BUP/SAM at
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP/SAM at 4-fold (8 mg/8 mg) and 8-fold (16 mg/16 mg) the therapeutic dose
Study: 30102427
Drug: Buprenorphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine alone (8 mg and 16 mg)
Study: 29045326
Drug: Strawberry (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry (25 g freeze-dried strawberries)
Study: 21206932
Drug: NitrAdine tablets
Normalized name: Nitrocine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NitrAdine tablets
Study: 15548480
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g mucuna preparation
Study: 11305824
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% with epinephrine 1:200,000 infiltrations (10 ml into the portals, 10 ml at the medial tibial incision site, 10 ml at the lateral femoral incision site, and 10 ml intra-articularly presurgically; 5 ml at the medial tibial incision and 10 ml at the lateral femoral incision postsurgically)
Study: 11305824
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% infiltrations (same administration as treatment group)
Study: 9158385
Drug: Trimetazidine treatment
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine treatment started twenty-four hours after percutaneous transluminal coronary angioplasty (PTCA) in 26 patients (Group I)
Study: 9158385
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without trimetazidine treatment (25 patients, Group II)
Study: 2437347
Drug: Dextran sulfate
Normalized name: dextran sulfate
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran sulfate (mild anticoagulant) for 7 to 56 months (average, 25.4 months)
Study: 27421623
Drug: Low-dose fluocinolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluocinolone acetonide implant (FAi)
Study: 27421623
Drug: High-dose fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluocinolone acetonide implant (FAi)
Study: 27421623
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide implant (FAi)
Study: 25042693
Drug: Sildenafil (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20mg 3× daily)
Study: 18277899
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) for steroid-dependent CD patients
Study: 11967597
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of subglottic area (SDSA) using a continuous infusion of a suspension containing polymyxin, tombramycin, and amphotericin B (n=30)
Study: 9989716
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone (5 mg or 10 mg daily) for 1 month
Study: 8528370
Drug: Tacrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine treatment for 14 months
Study: 24130358
Drug: Salsalate 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate 3.5 g/day
Study: 15982963
Drug: Out-of-Program service
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-of-Program service contact Days (OD) during Treatment (DT)
Study: 15982963
Drug: Out-of-Program services
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-of-Program services between 3 and 9 months post-treatment
Study: 11728816
Drug: Apocynin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apocynin (3 ml of 0.5 mg/ml) inhaled 2 times before and 6 times after O(3) exposure
Study: 3350281
Drug: Cimetidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (600 mg twice daily)
Study: 24099637
Drug: Levodopa (L-Dopa;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (L-Dopa; 100 mg)
Study: 22562746
Drug: Daily undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily undulating periodization (DUP)
Study: 19373103
Drug: Very deep
Normalized name: HOMOSALATE 5 g in 100 mL / OCTINOXATE 6.5 g in 100 mL / OXYBENZONE 1.2 g in 100 mL TOPICAL CREAM [Mary Kay CC Cream Sunscreen Broad Spectrum SPF 15 Very Deep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very deep sclerectomy with collagen implant (VDSCI)
Study: 18835931
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (25 ng . kg(‐1) . min(‐1))
Study: 15043569
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg lenograstim daily
Study: 15043569
Drug: 250 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 microg lenograstim daily
Study: 11355564
Drug: Triple-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-dose albendazole (400 mg for 3 consecutive days) plus praziquantel (40 mg/kg) plus iron supplementation (ferrous fumarate 200 mg weekly for 10 weeks)
Study: 11355564
Drug: Single-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose albendazole (400 mg) plus praziquantel (40 mg/kg)
Study: 11355564
Drug: Triple-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-dose albendazole (400 mg for 3 consecutive days) plus praziquantel (40 mg/kg)
Study: 11355564
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anthelmintic treatment)
Study: 11355564
Drug: Regular 6-monthly
Normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular 6-monthly anthelmintic treatment
Study: 9626461
Drug: Etanidazole (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanidazole (dose levels between 3 and 5.5 g/m2/day, total doses of 12, 16, 20, and 22 g/m2)
Study: 9626461
Drug: Etanidazole (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanidazole (16 g/m2 dose level)
Study: 9626461
Drug: High-dose ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ICE (ifosfamide, carboplatin, etoposide)
Study: 3144513
Drug: Budesonide (one-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (one-dose pretreatment)
Study: 3144513
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (one-dose pretreatment)
Study: 3144513
Drug: Terbutaline (one-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (one-dose pretreatment)
Study: 23807156
Drug: Elvitegravir once
Normalized name: Elvitegravir
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Elvitegravir once daily
Study: 20653670
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily)
Study: 20653670
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg once daily) + Placebo
Study: 20653670
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily) in patients with pre-treatment scores >18
Study: 20653670
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily) in second phase
Study: 20653670
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg once daily) + Placebo in second phase